Selected research
Industry Research
Hormone Refractory Prostate Cancer (HRPCA) Industry Research Report 2026
Market perspective
The global Hormone Refractory Prostate Cancer (HRPCA) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Hormone Refractory Prostate Cancer (HRPCA) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Hormone Refractory Prostate Cancer (HRPCA) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Hormone Refractory Prostate Cancer (HRPCA) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Hormone Refractory Prostate Cancer (HRPCA) include Sanofi S.A, Johnson & Johnson, Astellas Inc and Dendreon Corporation, Bayer AG, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Hormone Refractory Prostate Cancer (HRPCA) market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Hormone Refractory Prostate Cancer (HRPCA).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hormone Refractory Prostate Cancer (HRPCA) Market by Company
Sanofi S.A
Johnson & Johnson
Astellas Inc
Dendreon Corporation, Bayer AG
Hormone Refractory Prostate Cancer (HRPCA) Segment by Type
Vaccines
Cytotoxic Agents
Anti-Androgens
Radio-Pharmaceuticals
Hormone Refractory Prostate Cancer (HRPCA) Segment by Application
Specialty Clinics
Hospitals
Ambulatory Surgical Centers
Others
Hormone Refractory Prostate Cancer (HRPCA) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hormone Refractory Prostate Cancer (HRPCA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hormone Refractory Prostate Cancer (HRPCA) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hormone Refractory Prostate Cancer (HRPCA).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Hormone Refractory Prostate Cancer (HRPCA) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vaccines
- Cytotoxic Agents
- Anti-Androgens
- Radio-Pharmaceuticals
Applications
- Specialty Clinics
- Hospitals
- Ambulatory Surgical Centers
- Others
Companies covered
- Sanofi S.A
- Johnson & Johnson
- Astellas Inc
- Dendreon Corporation, Bayer AG
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Hormone Refractory Prostate Cancer (HRPCA) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Vaccines
- 2.2.3 Cytotoxic Agents
- 2.2.4 Anti-Androgens
- 2.2.5 Radio-Pharmaceuticals
- 2.3 Hormone Refractory Prostate Cancer (HRPCA) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Specialty Clinics
- 2.3.3 Hospitals
- 2.3.4 Ambulatory Surgical Centers
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Hormone Refractory Prostate Cancer (HRPCA) Breakdown Data by Type
- 3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Type (2021-2026)
- 3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Type (2027-2032)
4 Hormone Refractory Prostate Cancer (HRPCA) Breakdown Data by Application
- 4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Application (2021-2026)
- 4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Perspective (2021-2032)
- 5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Growth Trends by Region
- 5.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Region (2021-2026)
- 5.2.3 Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Region (2027-2032)
- 5.3 Hormone Refractory Prostate Cancer (HRPCA) Market Dynamics
- 5.3.1 Hormone Refractory Prostate Cancer (HRPCA) Industry Trends
- 5.3.2 Hormone Refractory Prostate Cancer (HRPCA) Market Drivers
- 5.3.3 Hormone Refractory Prostate Cancer (HRPCA) Market Challenges
- 5.3.4 Hormone Refractory Prostate Cancer (HRPCA) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Revenue
- 6.1.1 Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Revenue (2021-2026)
- 6.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Players (2021-2026)
- 6.2 Global Hormone Refractory Prostate Cancer (HRPCA) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Hormone Refractory Prostate Cancer (HRPCA) Head Office and Area Served
- 6.4 Global Hormone Refractory Prostate Cancer (HRPCA) Players, Product Type & Application
- 6.5 Global Hormone Refractory Prostate Cancer (HRPCA) Manufacturers Established Date
- 6.6 Global Hormone Refractory Prostate Cancer (HRPCA) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032)
- 7.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
- 7.4 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032)
- 8.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
- 8.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032)
- 9.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032)
- 10.2 South America Hormone Refractory Prostate Cancer (HRPCA) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
- 10.4 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032)
- 11.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi S.A
- 12.1.1 Sanofi S.A Company Information
- 12.1.2 Sanofi S.A Business Overview
- 12.1.3 Sanofi S.A Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2021-2026)
- 12.1.4 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
- 12.1.5 Sanofi S.A Recent Developments
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Information
- 12.2.2 Johnson & Johnson Business Overview
- 12.2.3 Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2021-2026)
- 12.2.4 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
- 12.2.5 Johnson & Johnson Recent Developments
- 12.3 Astellas Inc
- 12.3.1 Astellas Inc Company Information
- 12.3.2 Astellas Inc Business Overview
- 12.3.3 Astellas Inc Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2021-2026)
- 12.3.4 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
- 12.3.5 Astellas Inc Recent Developments
- 12.4 Dendreon Corporation, Bayer AG
- 12.4.1 Dendreon Corporation, Bayer AG Company Information
- 12.4.2 Dendreon Corporation, Bayer AG Business Overview
- 12.4.3 Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2021-2026)
- 12.4.4 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
- 12.4.5 Dendreon Corporation, Bayer AG Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst